GlobeNewswire Inc | Aug 25, 2020 09:00AM EDT

August 25, 2020

NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acers management team will provide a virtual corporate overview at upcoming investor conferences in September, including the LD Micro 500 Virtual Conference and the H.C. Wainwright 22nd Annual Global Investment Conference.

Acer Conference Presentation Details:

Conference: LD Micro 500 Virtual ConferenceDate: Tuesday, September 1, 2020Time: 3 p.m. Eastern Time Conference: H.C. Wainwright 22^nd Annual Global Investment ConferenceDate: Tuesday, September 15, 2020Time: 2:30 p.m. Eastern Time

More information on Acer presentations can be found in the Events and Presentations section of Acers website at https://www.acertx.com/investor-relations/events-presentations/.

About Acer Therapeutics Inc.

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acers pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.

Investor Contact:Hans VitzthumLifeSci AdvisorsPh: 617-430-7578hans@lifesciadvisors.com

Jim DeNikeAcer Therapeutics Inc.Ph: 844-902-6100jdenike@acertx.com